(NASDAQ: RVMD) Revolution Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.
Revolution Medicines's earnings in 2026 is -$1,371,701,000.On average, 24 Wall Street analysts forecast RVMD's earnings for 2026 to be -$1,723,774,633, with the lowest RVMD earnings forecast at -$1,835,515,334, and the highest RVMD earnings forecast at -$1,607,229,253. On average, 23 Wall Street analysts forecast RVMD's earnings for 2027 to be -$1,252,448,277, with the lowest RVMD earnings forecast at -$2,237,620,282, and the highest RVMD earnings forecast at $214,297,234.
In 2028, RVMD is forecast to generate -$547,499,669 in earnings, with the lowest earnings forecast at -$1,447,994,503 and the highest earnings forecast at $1,151,847,631.